The C-terminal domain of chondroadherin: A new regulator of osteoclast motility counteracting bone loss

Journal of Bone and Mineral Research

Volumn 29, Issue 8, 2014, Pages 1833-1846

  Capulli, Mattia ^a   Olstad, Ole K ^b   Önnerfjord, Patrik ^c   Tillgren, Viveka ^c   Muraca, Maurizio ^d   Gautvik, Kaare M ^b   Rucci, Nadia ^a   Teti, Anna ^a  

^a UNIVERSITY OF L'AQUILA   (Italy)

^b ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^c LUND UNIVERSITY   (Sweden)

^d BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

Author keywords

Chondroadherin; Osteoclasts; Osteoporosis

Indexed keywords

ALENDRONIC ACID; ALP PROTEIN; ALPHA2BETA1 INTEGRIN RECEPTOR; BOTULINUM TOXIN A; CHONDROADHERIN; COLLAGEN TYPE 1; CYCLOPEPTIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTEGRIN RECEPTOR; MIGFILIN; NITRIC OXIDE; NITRIC OXIDE DONOR; OSTEOCALCIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPONTIN; OXYGENASE INHIBITOR; PENICILLAMINE DERIVATIVE; PROTEIN; TRANSCRIPTION FACTOR RUNX2; UNCLASSIFIED DRUG; VASODILATOR STIMULATED PHOSPHOPROTEIN; BONE DENSITY CONSERVATION AGENT; PEPTIDE; SCLEROPROTEIN;

ADULT; AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE BIOPSY; BONE MARROW CELL; BONE MASS; BONE METABOLISM; CARBOXY TERMINAL SEQUENCE; CARTILAGE CELL; CELL DENSITY; CELL DIFFERENTIATION; CELL MIGRATION; CELL MOTILITY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; FEMALE; FEMUR; GENE EXPRESSION; HUMAN; HUMAN TISSUE; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; MICROARRAY ANALYSIS; MONOCYTE; MOUSE; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOCLAST ACTIVITY; OSTEOCLASTOGENESIS; OSTEOLYSIS; OVARIECTOMY; POSTMENOPAUSE OSTEOPOROSIS; PRIMARY OSTEOPOROSIS; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; TRABECULAR BONE; ANIMAL; CELL CULTURE; CELL MOTION; CHEMISTRY; DISEASE MODEL; DRUG EFFECTS; GENE EXPRESSION PROFILING; GENETICS; METABOLISM; MIDDLE AGED; WESTERN BLOTTING;

AGED; ANIMALS; BLOTTING, WESTERN; BONE DENSITY CONSERVATION AGENTS; BONE RESORPTION; CELL DIFFERENTIATION; CELL MOVEMENT; CELLS, CULTURED; DISEASE MODELS, ANIMAL; EXTRACELLULAR MATRIX PROTEINS; FEMALE; GENE EXPRESSION PROFILING; HUMANS; MICE; MIDDLE AGED; OSTEOCLASTS; OVARIECTOMY; PEPTIDES;

EID: 84904623430     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.2206     Document Type: Article

References (38)

1. Neame PJ, Sommarin Y, Boynton RE, Heinegård D., The structure of a 38-kDa leucine-rich protein (chondroadherin) isolated from bovine cartilage. J Biol Chem. 1994; 269 (34): 21547-54.
2. Camper L, Heinegård Lundgren-Åkerlund E., Integrin alpha2beta1 is a receptor for the cartilage matrix protein chondroadherin. J Cell Biol. 1997; 138 (5): 1159-67.
3. Grover J, Chen X-N, Korenberg JR, Roughley PJ., The structure and chromosome location of the human chondroadherin gene. Genomics. 1997; 45 (2): 379-85.
4. Landgren C, Beier DR, Fässler R, Heinegård D, Sommarin Y., The mouse chondroadherin gene: characterization and chromosomal localization. Genomics. 1998; 47 (1): 84-91.
5. Wilda M, Bächner D, Just W, et al. Comparison of the expression pattern of five genes of the family of small leucine-rich proteoglycans during mouse development. J Bone Miner Res. 2000; 15 (11): 2187-96.
6. Shen Z, Gantcheva S, Mansson B, Heinegård D, Sommarin Y., Chondroadherin expression changes in skeletal development. Biochem J. 1998; 330 (Pt 1): 549-57.
7. Månsson B, Wenglén C, Mörgelin M, Saxne T, Heinegård D., Association of chondroadherin with collagen type II. J Biol Chem. 2001; 276 (35): 32883-8.
8. Haglund L, Tillgren V, Addis L, Wenglén C, Recklies A, Heinegård D., Identification and characterization of the integrin alpha2beta1 binding motif in chondroadherin mediating cell attachment. J Biol Chem. 2011; 286 (5): 3925-34.
9. Mizuno M, Fujisawa R, Kuboki Y., Bone chondroadherin promotes attachment of osteoblastic cells to solid-state substrates and shows affinity to collagen. Calcif Tissue Int. 1996; 59 (3): 163-7.
10. Wiberg C, Heinegård D, Wenglén C, Timpl R, Mörgelin M., Biglycan organizes collagen VI into hexagonal-like networks resembling tissue structures. J Biol Chem. 2002; 277 (51): 49120-6.
11. Wiberg C, Klatt AR, Wagener R, et al. Complexes of matrilin-1 and biglycan or decorin connect collagen VI microfibrils to both collagen II and aggrecan. J Biol Chem. 2003; 278 (39): 37698-704.
12. Reppe S, Refvem H, Gautvik VT, et al. Eight genes are highly associated with BMD variation in postmenopausal Caucasian women. Bone. 2010; 46 (3): 604-12.
13. Önnerfjord P, Khabut A, Reinholt FP, Svensson O, Heinegård D., Quantitative proteomic analysis of eight cartilaginous tissues reveals characteristic differences as well as similarities between subgroups. J Biol Chem. 2012; 287 (23): 18913-24.
14. Caselli G, Mantovanini M, Gandolfi CA, et al. Tartronates: a new generation of drugs affecting bone metabolism. J Bone Miner Res. 1997; 12 (6): 972-81.
15. Sikora GA, Gelbard A, Davies MA, et al. Targeted inhibition of inducible nitric oxide synthase inhibits growth of human melanoma in vivo and synergizes with chemotherapy. Clin Cancer Res. 2010; 16 (6): 1834-44.
16. Rufo A, Del Fattore A, Capulli M, et al. Mechanisms inducing low bone density in Duchenne muscular dystrophy in mice and humans. J Bone Miner Res. 2011; 26 (8): 1891-903.
17. Warner SE, Sanforda DA, Beckera BL, Bainb SD, Srinivasana S, Grossa TS., Botox induced muscle paralysis rapidly degrades bone. Bone. 2006; 38 (2): 257-64.
18. Alam I, Gray AK, Chu K, et al. Generation of the first autosomal dominant osteopetrosis type II (ADO2) disease models. Bone. 2014; 59: 66-75.
19. Feldkamp LA, Davis LC, Kress JW., Practical cone-beam algorithm. J Opt Soc Am. 1984; 1 (6): 612-9.
20. Lorensen WE, Cline HE., Marching cubes: a high resolution 3d surface construction algorithm. SIGGRAPH Comput Graph. 1987; 21 (4): 163-9. DOI: 10.1145/37402.37422.
21. Pratt WK., Digital image processing. 2nd ed. New York: Wiley; 1991.
22. Bouxsein ML, Boyd SK, Christiansen BA, Guldberg RE, Jepsen KJ, Müller R., Guidelines for assessment of bone microstructure in rodents using micro-computed tomography. J Bone Miner Res. 2010; 25 (7): 1468-86.
23. Rucci N, Rufo A, Alamanou M, et al. The glycosaminoglycan-binding domain of PRELP acts as a cell type-specific NF-kappaB inhibitor that impairs osteoclastogenesis. J Cell Biol. 2009; 187 (5): 669-83.
24. Dempster DW, Compston JE, Drezner MK, et al. Standardized nomenclature, symbols, and units for bone histomorphometry: a 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res. 2013; 28 (1): 2-17.
25. Yaroslavskiy BB, Zhang Y, Kalla SE, et al. NO-dependent osteoclast motility: reliance on cGMP-dependent protein kinase I and VASP. J Cell Sci. 2005; 118 (Pt 23): 5479-87.
26. Klinck J, Boyd SK., The magnitude and rate of bone loss in ovariectomized mice differs among inbred strains as determined by longitudinal in vivo micro-computed tomography. Calcif Tissue Int. 2008; 83: 70-9.
27. Teitelbaum SL., The osteoclast and its unique cytoskeleton. Ann N Y Acad Sci. 2011; 1240: 14-7.
28. Ishi T, Kikuta J, Kubo A, Ishii M., Control of osteoclast precursor migration: a novel point of control for osteoclastogenesis and bone homeostasis. IBMS Bonekey. 2010; 7 (8): 279-86. DOI: 10.1138/20100459.
29. Kleinert H, Pautz A, Linker K, Schwarz PM., Regulation of the expression of inducible nitric oxide synthase. Eur J Pharmacol. 2004; 500 (1-3): 255-66.
30. Mancardi D, Pla AF, Moccia F, Tanzi F, Munaron L., Old and new gasotransmitters in the cardiovascular system: focus on the role of nitric oxide and hydrogen sulfide in endothelial cells and cardiomyocytes. Curr Pharm Biotechnol. 2011; 12 (9): 1406-15.
31. Amitai Y., Physiologic role for "inducible" nitric oxide synthase: a new form of astrocytic-neuronal interface. Glia. 2010; 58 (15): 1775-81.
32. Gao Y., The multiple actions of NO. Pflugers Arch. 2010; 8459 (6): 829-39.
33. Zhang Y, Tu Y, Gkretsi V., Wu C. Migfilin interacts with vasp and regulates vasp localization to cell-matrix adhesions and migration. J Biol Chem. 2006; 281 (18): 12397-407.
34. Teti A., Bone development: overview of bone cells and signaling. Curr Osteoporos Rep. 2011; 9 (4): 264-73.
35. Baron R, Hesse H., Update on bone anabolics in osteoporosis treatment: rationale, current status, and perspectives. J Clin Endocr Metab. 2012; 97: 311-25.
36. Hessle L, Stordalen GA, Wenglén C, et al. The skeletal phenotype of chondroadherin deficient mice. PLoS One. 2013; 8: e63080.
37. Frost HM., Perspective on the trabecular "thickness"-number problem. J Bone Miner Res. 1999; 14 (11): 1816-21.
38. Bargman R, Posham R, Boskey AL, DiCarlo E, Raggio C, Pleshko N., Comparable outcomes in fracture reduction and bone properties with RANKL inhibition and alendronate treatment in a mouse model of osteogenesis imperfecta. Osteoporosis Int. 2012; 23 (3): 1141-50.